Cartesian Therapeutics, Inc.
Descartes-08
myasthenia gravis
Countdown
178days
Phase 3 readout · ~ Jan 1, 2027 estimated
What's at stake
Phase 3 trial results for Descartes-08 in myasthenia gravis are due ~ Jan 1, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“topline data from the Phase 3 AURORA trial in the first quarter of 2027”